研究单位：[1]Guangdong Association of Clinical Trials[2]Beijing Friendship Hospital,Capital Medical University[3]Chongqing University Three Gorges Hospital[4]The First People's Hospital of Foshan[5]Fujian Medical University Union Hospital[6]Affiliated Cancer Hospital of Guangzhou Medical University
A prospective, multicenter clinical study designed to explore the efficacy of postoperative adjuvant EGFR-TKIs therapy based on MRD status in patients with stage IB-IIIB EGFR-mutant non-squamous non-small cell lung cancer (non-squamous NSCLC). Primary endpoints include 3-year Disease-Free Survival rate (3y-DFS) and median disease-free survival (mDFS).
